Manuscript Development
Palatin
Challenge
Palatin Technologies had a goal to inform the ocular scientific community about the benefits of targeting the Melanocortin Pathway. One of the ways i2Vision achieved this was by co-creating a supplement: Melanocortin Pathway: A New Target for Ocular Disease Therapy.
Solution
Therapeutically targeting the melanocortin pathway represents a novel approach to the treatment of inflammatory and immune mediated diseases. Preclinical evidence has demonstrated the broad range of biological activity of melanocortin agonists in numerous inflammatory diseases, including ophthalmic diseases. The role of synthetic MCr receptor agonists shows promise in the treatment of uveitis and retinopathy in preclinical animal models.
Additionally, i2Vision strived to outline the results of the phase 2 study treatment with PL9643, which showed improved signs and symptoms in patients with moderate to severe dry eye disease.
Manuscript Development
-
- Research Analysis
- Scientific Strategy
- Medical Writing
-
- Media Planning
- Design & Layout